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Abstract 
Composite endpoints are commonly used as the primary measure of efficacy in heart failure 
clinical trials to assess the overall treatment effect and to increase the efficiency of trials.  
Clinical trials still must enroll large numbers of patients to accrue a sufficient number of 
outcome events and have adequate power to draw conclusions about the efficacy and safety of 
new treatments for heart failure.  Additionally, the societal and health-system perspectives on 
heart failure have raised interest in ascertaining the effects of therapy on outcomes such as repeat 
hospitalization and the patient’s burden of disease.  Thus, novel methods for using composite 
endpoints in clinical trials (e.g., clinical status composite endpoints, recurrent event analyses) are 
being applied in current and planned trials.  Endpoints that measure functional status or reflect 
the patient experience are important but used cautiously because heart failure treatments may 
improve function yet have adverse effects on mortality.  This paper discusses the use of 
traditional and new composite endpoints, identifies qualities of robust composites, and outlines 
opportunities for future research. 
 
Keywords:  heart failure, clinical trial, endpoint determination, surrogate endpoints 
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INTRODUCTION 
 Composite endpoints are increasingly used as primary efficacy measures in heart failure 
clinical trials (Supplemental Appendix Table 1)1 to provide a comprehensive picture of the 
treatment effect, and to improve trial efficiency by increasing the event rate and reducing the 
required sample size.  They have advantages and disadvantages (Table 1),1-4 but composite 
endpoints are generally accepted by academics, clinicians, and regulators when the components 
are well-defined, specific to the key objective of interest, and broadly congruent in regards to 
treatment effect.  They are problematic when the overall effect suggests no benefit, or even harm, 
in one or more components.   
 The adoption of evidence-based therapies has reduced event rates for well-established 
composites (e.g., all-cause mortality plus cardiovascular hospitalization; cardiovascular death 
plus heart failure hospitalization).  Thus, large studies with long follow-up are still needed in 
modern trials to accrue a sufficient number of events for adequate statistical power.  These 
studies require substantial investment from funders (e.g., public or industry sources) who must 
decide whether to commit significant funds when there is a real risk that the therapy will be 
ineffective.  Industry investment in cardiovascular drug development has been decreasing, 
perhaps in part because of these reasons,5;6 and cardiovascular disease is no longer one of the top 
ten therapeutic areas for research and development.7 
 It is a matter of debate whether the composite of cardiovascular mortality or heart failure 
hospitalization is the most meaningful and clinically relevant endpoint.  New endpoints (e.g., 
novel clinical composites, functional measures, or patient reported outcomes) or analytic 
methodologies (e.g., recurrent event analyses, responder analyses) might serve the dual purpose 
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of more accurately reflecting the modern heart failure patient’s disease burden and improving 
trial efficiency.  However, confirmation of their validity is needed before they can achieve 
widespread acceptance.   
 The Cardiovascular Round Table (CRT) of the European Society of Cardiology (ESC) 
convened a two-day workshop to explore how existing and innovative composite endpoints can 
be leveraged to advance the conduct of heart failure clinical trials and, ultimately, patient care.  
Workshop participants identified five qualities that should characterize composite endpoints in 
heart failure clinical trials (Table 2).  This paper summarizes the key insights and discussions, 
suggests approaches for using composite endpoints, and identifies knowledge gaps that need to 
be addressed by further research.   
 
OVERVIEW OF COMPOSITE ENDPOINTS IN HEART FAILURE TRIALS 
Fatal and Non-Fatal Composite Clinical Outcomes 
 All-cause assessments of fatal and non-fatal outcomes (e.g., all-cause mortality plus all-
cause hospitalization) reflect an intervention’s net benefit.  Since a single intervention is unlikely 
to reduce all modes of death or causes of hospitalization, a significant reduction in an all-cause 
composite endpoint can be interpreted to indicate that the intervention reduced the major causes 
of death or hospitalization (usually cardiovascular in heart failure trials) without significant 
adverse effects.1 
 Estimated treatment effects may be diluted if a substantial proportion of events are not 
influenced by the treatment.8  A greater number of events will increase statistical power only if 
those additional events are potentially modifiable by the intervention.  The addition of outcomes 
that are not influenced by the treatment will reduce the measured treatment effect and the study 
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power.  Thus, composite endpoints should only include components that are relevant to the 
population being studied and have biological plausibility to support an expected treatment 
benefit on each component.  A significant risk reduction in a composite endpoint does not 
necessarily imply that the risk reduction is equal across each component.  Statistical methods to 
test for heterogeneity of treatment effect across individual components of a composite endpoint 
have been described but are likely to be underpowered.9;10  Typically, reporting the individual 
components and testing the treatment effect on each is sufficient.  
 Similar logic applies to all-cause versus cause-specific endpoints.  The Candesartan in 
Heart Failure Assessment of Reduction in Mortality and Morbidity (CHARM) trials, which 
included a broad spectrum of heart failure patients, used all-cause mortality as the primary 
endpoint for the overall program.11  Out of 1831 deaths, 371 were non-cardiovascular and 
unlikely to be influenced by cardiovascular therapy.  While the unadjusted hazard ratio (HR) for 
the effect of candesartan on all-cause mortality was not statistically significant (HR 0.91, 95% 
confidence interval [CI] 0.83-1.00, p=0.055), the effect on cardiovascular mortality (a cause-
specific endpoint) was significant (HR 0.88, CI 0.79-0.97, p=0.012).11 
 Owing in part to this experience, heart failure trials are often now designed with cause-
specific composite endpoints (e.g., cardiovascular mortality or heart failure hospitalization).  
Cause-specific endpoints reflect a more precise evaluation of an intervention’s expected effect, 
since it is unlikely that a cardiovascular drug will reduce non-cardiovascular causes of death 
(e.g., cancer, accidents).  When cause-specific primary endpoints are used, all-cause mortality 
should still be evaluated as a secondary or safety endpoint to ensure that survival is not adversely 
affected by another pathway.  The effect on all-cause mortality should be directionally similar to 
the effect on cardiovascular mortality (if the majority of deaths are disease-related), even if the 
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effect on all-cause mortality is not statistically significant.  If cardiovascular mortality is 
significantly reduced and all-cause mortality is shifted towards the null, further analyses are 
needed to explain the findings and explore whether some component of non-cardiovascular 
mortality was increased in the treated versus the control arm.  Similarly, discordant results in 
individual components may be concerning and warrant further investigation, even if risk is 
reduced in the overall composite.  Such analyses are exploratory and not likely to be definitive 
(depending on the number of events), but they can inform further research strategies to clarify 
the non-cardiovascular or discordant effects. 
 Limitations of cause-specific endpoints include the need for specific event definitions and 
endpoint adjudication.  The precision of adjudication depends on complete medical records, 
which may be limited for out-of-hospital deaths or some regions in global trials.  External factors 
(e.g., geographical standards of care, threshold for admission, reimbursement pressures, 
availability of outpatient treatment, and medical or dietary non-adherence) may influence cause-
specific hospitalization, although proper randomization should minimize the impact of these 
factors.  These factors may have greater impact if a majority of patients are enrolled in regions 
with large differences  in standards of care. 
 Reporting the individual components of composite endpoints is important to examine 
whether or not they are concordant, but non-fatal endpoints should not be analyzed 
independently because of the problem of competing risks.12  Composite endpoints can solve this 
dilemma if they include both fatal and non-fatal events.  However, analyzing fatal and non-fatal 
events in a composite endpoint can be problematic because these events differ in their 
importance.  The least serious events (i.e., hospitalizations in heart failure trials, non-fatal 
myocardial infarctions in acute coronary syndrome trials) usually occur earlier than more serious 
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events (i.e. death).  Time-to-event analysis focuses on the first event.  Thus, composite endpoints 
are often driven by the least serious component,13 which decreases the relevance (not confidence) 
of any finding.  For example, in the Systolic Heart Failure Treatment with the If Inhibitor 
Ivabradine Trial (SHIFT) study, the primary endpoint was a composite of cardiovascular death or 
hospital admission for worsening heart failure.14  Ivabradine reduced the risk of the primary 
endpoint compared with placebo in patients with a heart rate ≥70 beats per minute (HR 0.82, CI 
0.75-0.90, p<0.0001), mainly driven by a reduction in heart failure hospitalizations (16% vs. 
21%, HR 0.74, CI 0.66-0.83, p<0.0001) with no effect on cardiovascular mortality (14% vs. 
15%, HR 0.91, CI 0.80-1.03, p=0.13).14  The European Medicines Agency (EMA) approved 
ivabradine, but only for patients with heart rates above 75 beats per minute where a possible 
nominal reduction in overall mortality was observed.15  Food and Drug Administration (FDA) 
approval was recently granted for a reduction in heart failure hospitalization in patients with a 
heart rate ≥70 beats per minute.  Based on results from the Valsartan Heart Failure Trial (Val-
HeFT), valsartan was approved by the FDA to reduce hospitalization for heart failure, with no 
indication for improvement in mortality because it reduced only one of the two primary 
endpoints:  1) all-cause mortality (relative risk 1.02, CI 0.88-1.18, p=0.80) and 2) the composite 
of all-cause mortality or cardiac arrest with resuscitation, hospitalization for heart failure, or 
administration of intravenous inotropes or vasodilators for ≥4 hours without hospitalization 
(relative risk 0.87, CI 0.77-0.97, p=0.009).  The beneficial effect of valsartan on the latter was 
driven by a reduction in heart failure hospitalization.16  Statistical methods to weight outcomes 
according to severity have been proposed in heart failure and other disease states.17-22  However, 
these approaches are limited by lack of consensus on the relative weighting of events and 
inconsistency across studies. 
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 These examples underscore the importance of limiting composites to include events that 
are clinically meaningful and considered to be modifiable.  It is highly recommended that 
regulatory agencies be involved early in the process of constructing composite endpoints for use 
in pivotal trials. 
 
Clinical Status Composite Endpoints 
 In chronic conditions such as heart failure, mortality is not the only meaningful efficacy 
measure, since a patient may be alive but have a poor clinical status, functional capacity, or 
quality of life.23  A treatment may be worthwhile and considered valuable by patients when it 
improves their clinical status even if it does not prolong their survival.24;25  A clinical status 
composite endpoint has been developed26 and used27-30 in heart failure trials (with adaptations 
appropriate for the study population).  Patients are categorized as improved (moderate or marked 
improvement in clinical status at all planned assessments without hospitalization for heart failure 
or death); unchanged (modest improvement or worsening in clinical status); or worsened 
(moderate or marked worsening of clinical status at any planned assessment, hospitalization for 
heart failure requiring intravenous or mechanical interventions, or death).  The distribution of 
responses can be compared between treatment groups without assigning ranks or worse scores to 
the individual components.26  This method has the advantage of describing the patient’s clinical 
course and response to treatment, but more experience is needed to validate that it produces a 
reliable, clinically meaningful, and unbiased estimate of treatment effect.  Analyses can 
determine if a statistically significant difference exists in the distribution of patients who 
improved, worsened, or were unchanged, but the magnitude or clinical relevance of the effect 
can be challenging to interpret.  Achieving consensus regarding what constitutes clinically 
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meaningful degrees of improvement and worsening (recognizing that the criteria will differ to 
some extent by study population) is one challenge of implementing this endpoint.  Variation in 
standards for hospitalizations across geographic regions may also be problematic, but capturing 
moderate to marked worsening in symptoms or functional status might minimize the problem of 
geographic variation in standards of care.  Finally, experience with this endpoint suggests that it 
is most appropriate for relatively short-term trials (<9 months) because of the challenges related 
to assessing changes in a patient’s clinical improvement over lengthy time periods (i.e., patient 
recall) and because more clinical events accrue during long-term follow-up which outweigh the 
clinical status improvement component of the composite. 
 
FUNCTIONAL ENDPOINTS 
 Most clinicians agree that functional impairment is a primary concern for patients with 
heart failure.  For some patients, improved functional status or quality of life is of greater 
importance than longevity.24;25  Patients are surviving longer with heart failure because of 
therapeutic advances,31 so assessing functional status may be of even greater importance in this 
era of improved survival.  The primary goal of considering novel composite endpoints that 
include functional status or patient reported symptom measures is to identify treatments that 
improve important aspects of patient well-being beyond survival.  However, few, if any, 
cardiovascular drugs have been approved on the basis of improved functional status alone.  
Regulators have been cautious about functional-status endpoints in cardiovascular clinical trials 
because of agents that improved exercise tolerance but increased mortality in large trials (e.g., 
flosequinan).32  The problem of defining a clinically meaningful change in exercise time (or 
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other measure of functional status) also contributes to the uncertainty about the value of this 
endpoint. 
 A clinically meaningful improvement in functional status may lead to approval of a new 
therapeutic agent, provided that an adequate margin of safety can be assured.1  A stringent 
margin for excluding an adverse effect on mortality would likely be required in a trial using a 
functional primary endpoint.  Thus, efficiencies gained by using novel composites may be offset 
by the need to demonstrate safety, since studies would still need to be large and long enough to 
rule out an increased risk of mortality (at some threshold level acceptable to regulatory agencies) 
or provide reasonable assurance of a neutral effect on mortality.   
 The persisting question is what endpoint(s) (other than death or hospitalization) might be 
clinically relevant and scientifically valid, while also increasing the efficiency of drug 
development and clinical trial conduct.  The 6-minute walk test distance has been the primary 
endpoint in most registration trials of pulmonary artery hypertension,33;34 accepted by both EMA 
and FDA, but it has not been recognized as adequate in heart failure.  Other functional measures 
such as peak VO2 might be candidate endpoints for heart failure trials, but they are 
unphysiological, can be influenced by patient motivation and skeletal muscle function, and may 
not be consistently reproducible, which limits their use as an endpoint in heart failure and other 
(e.g., pulmonary hypertension) trials.  Health-related quality of life as measured by instruments 
such as Minnesota Living With Heart Failure Score (MLWHF) or the Kansas City 
Cardiomyopathy Questionnaire (KCCQ) might be considered as endpoints and have been used in 
many studies, but the FDA has specific standards that must be met when patient reported 
outcomes are used to support labeling claims.35;36  While health-related quality of life 
assessments are clinically relevant and can be informative, the methodologic problems of using 
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such scores in efficacy assessments (e.g., potential for bias particularly in unblinded studies, 
procedures for handling missing data) are well known.35  Whether regulatory agencies would 
accept the MLWHF or KCCQ as supportive evidence of efficacy remains to be seen and would 
likely need to be considered on an individual trial basis.  
 Finally, another important consideration is the health technology assessment of new 
drugs after regulatory approval.  Even if an endpoint such as 6-minute walk distance were 
accepted by regulators, it is uncertain whether payers would view it as a worthwhile endpoint.  
Research would need to validate the level of increased exercise tolerance that was cost-effective 
and had a societal benefit.   
 
Role of Adaptive Licensing 
 In 2007, EMA described its openness to innovative drug development approaches.37  One 
such initiative is the Pilot Project on Adaptive Licensing.38  Adaptive licensing involves an 
authorized limited indication followed by “iterative phases of evidence gathering and progressive 
licensing adaptations concerning both the authorized indication and the potential further 
therapeutic uses of the drug”.38  With adaptive licensing, a drug could be approved based on 
improvement in a well-defined functional endpoint within a rigorously conducted clinical trial.  
After licensing, post-authorization efficacy and safety studies would be required.38-40  This 
process fulfils the goal of accelerating patient access to new drugs, while providing a mechanism 
for collecting safety data.  Functional status or patient-reported symptom endpoints could have a 
role in adaptive licensing, but past experiences in heart failure where initially promising drugs 
have later been found harmful (e.g., ibopamine, flosequinan) emphasize the need to pursue this 
approach cautiously.  Many issues have been identified with this approach.  First, it is uncertain 
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if a relatively short-term trial assessing a functional endpoint will accrue a sufficient number of 
events to provide early estimates of safety prior to granting an adaptive license.  Additionally, 
the safety margin for excluding excess risk needs to be defined and achieving harmonization 
among regulatory bodies could be problematic.  Presumably, the acceptable safety margin could 
vary by patient population, severity of illness, or the pre-test probability of risk in the context of 
the mechanism of action of the drug or device; thus, safety estimates should account for this 
variation.  On the other hand, the adaptive approval process aims to accrue pharmacovigilance 
data in the early phase of marketing through registries, thereby monitoring the real-life use and 
adverse event rates of the drugs approved with this regulatory pathway.41  Conducting 
randomized clinical trials after a drug is marketed and available to patients is more difficult than 
pre-approval from the standpoint of subject recruitment and retention.  All patients receiving the 
drug could be followed in a registry for safety, but the results of observational studies are less 
reliable because of the potential for bias.  The current system is not optimally designed to allow 
regulators to enforce withdrawal of adaptive licences if the sponsor does not uphold the 
requirements of the licence (e.g., follow-up trials are not completed, a concerning safety signal 
emerges but falls short of crossing pre-defined margins of licence withdrawal, safety trials are 
poorly designed), particularly in the European Union where decisions to withdraw drugs are 
made by each member state.  One approach would be to apply adaptive licensing only to 
severely ill patients where the balance of risks and benefits might be more favourable.  However, 
once marketed, restrictions on use according to patient severity will be difficult to enforce. 
 
STATISTICAL CONSIDERATIONS:  NEW ANALYTIC METHODS 
Recurrent Event Analyses 
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 Heart failure is a chronic disease, typically characterized by repeat hospitalizations as a 
patient’s condition progressively worsens.  Several factors have contributed to an interest in 
analysing recurrent events in heart failure trials.42  Hospitalization is the major contributor to the 
overall cost of heart failure care,43 which has led to targeted interventions to reduce 
readmissions.44;45  Therefore, data describing an intervention’s effect on recurrent events is 
highly clinically relevant.  Importantly, restricting analyses to first events incompletely 
represents the patient’s overall burden of disease, since first events account for only half of the 
total number of heart failure hospitalizations in major clinical trials.46-49  Several approaches to 
recurrent event analyses have been tested using major heart failure trial datasets.46-51  All have 
limitations, as complex assumptions are made in determining the study sample size and in the 
statistical modelling.52  One concern is overestimation of the treatment effect,48 and another is 
how best to manage the competing risk of death.  Either the joint frailty model or the negative 
binomial distribution (if death rates are low) have been used,48;50 but none of the methods have 
been well validated.  Regulatory acceptance of the methodology is a critical aspect, and the 
agencies appear to be supportive of an analysis strategy based on recurrent events.  The primary 
endpoint of the PARAGON-HF study (Prospective Comparison of ARNI with ARB Global 
Outcomes in Heart Failure With Preserved Ejection Fraction, NCT01920711) is the cumulative 
number of primary composite events of cardiovascular death and total (first and recurrent) heart 
failure hospitalizations.53  PARAGON-HF was also designed to have reasonable power on a 
standard time-to-first event analysis for sensitivity comparisons.  This approach allows regulators 
and investigators to gain experience with a recurrent-events method against a background of 
traditional time-to-first event analysis. 
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Responder Analyses 
 Responder analyses are used to assess the clinical relevance of an observed treatment 
effect.36;54;55  From the EMA perspective, responder analyses have been used in studies of 
obesity (e.g., comparison of proportion of patients with ≥10% weight loss), acute stroke (e.g., 
comparison of proportion of survivors who regain functional independence), or depression (e.g., 
comparison of proportion of patients achieving a threshold change in symptom scores).  The 
challenge with responder analyses, especially in heart failure trials, is defining, validating, and 
achieving consensus on the clinically meaningful change in a functional measure or symptom 
score.35;56-58  In the context of a heart failure trial, a responder analysis could be based on a 
surrogate variable that is expected to be related to reliable clinical improvement or clinical 
outcome.  Historically, measures of functional status on which responder analyses might be 
based (e.g., exercise time, left ventricular size, ejection fraction, haemodynamics) inconsistently 
correlate with clinical outcome.  Scales to measure symptoms, dyspnoea, functional status, and 
health-related quality of life are alternatives to surrogates and have been used across clinical 
trials.  Interpretation of treatment effect is difficult since effect size for the same treatment can 
differ when measured on different scales, and definition of a clinically important change can be 
arbitrary and that attenuation of decline, i.e. no change, may itself be an indicator of benefit.  
Importantly, study power can be substantially reduced in a responder analysis when a continuous 
outcome measure is dichotomized.59   
 Responder analyses might be useful in phase I and II trials to help inform phase III 
designs and patient selection criteria; however, many well-known examples exist where 
favorable phase II results did not translate into improved outcome in phase III.60  Therefore, 
cautious interpretation of phase II results used for this purpose is advised.  On the other hand, if 
16 
 
efficacy is demonstrated using traditional methods, responder analyses can be performed 
secondarily to characterize the clinical relevance of the effect and to evaluate the potential for 
hyper-responders (in cardiac resynchronization therapy trials often called super-responders), 
non-responders, or patients who experience harm.  Signals of efficacy or harm observed in 
subgroups are far from definitive, but they can generate new hypotheses for testing in adequately 
powered studies within the specific population that appeared to have the greatest treatment 
effect.  Assessing heterogeneity of benefit or net benefit, balancing benefit and harm, using 
subgroups based on a risk score has been proposed as a more powerful approach to subgroup 
analysis.61;62  Responder analyses are also of interest to support health technology assessment.  
However, it is critical to acknowledge the limitations of these analyses to avoid over 
interpretation of the data.   
 
CONCLUSION 
 The changing landscape for heart failure clinical trials has created an important 
opportunity to learn from past successes (and failures) and shape future approaches.  The use of 
traditional composite endpoints has yielded many highly effective therapies, and the approach 
should not be abandoned.  However, the overall health burden from heart failure on patients is 
broader than hospitalizations and death, and it will be important to conduct trials that reflect 
endpoints important to patients35 (and payers).  Further, the declining resources for conducting 
larger, longer, and more costly trials is a reality that cannot be ignored.5  Composites that reflect 
both clinical status and traditional “hard” events, new analytic methodologies to assess recurrent 
events, and renewed efforts to assess changes in functional status (without ignoring safety) are 
areas of both interest and uncertainty that will benefit from additional research (Table 3).  
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Ongoing trials will provide more insight into the strengths and weaknesses of these approaches 
and inform future directions in heart failure research.
18 
 
 
Acknowledgements 
This paper was generated from discussions during a Cardiovascular Round Table (CRT) 
Workshop organized on 21-22 January 2015 by the European Society of Cardiology (ESC).  The 
CRT is a strategic forum for high-level dialogues between industry and ESC leadership to 
identify and discuss key strategic issues for the future of cardiovascular health in Europe. 
 
The opinions expressed in this paper are those of the authors and cannot be interpreted as the 
opinion of any of the organizations that employ the authors. 
 
The authors acknowledge the contribution of Caroline Boulton for participating in the discussion 
at the ESC CRT workshop from which this paper originated. 
 
Conflicts of Interest 
Stefan D. Anker:  Research grants from Vifor and Abbott Vascular; personal fees from Vifor, 
Abbott Vascular, Bayer Pharma, Novartis, Lonestar Heart, Respicardia, ZS Pharma, Relypsa, 
Biotronik, Cardiorentis, Servier 
Stefan Schroeder:  Employee of Bayer Healthcare 
Dan Atar:  Personal fees from Astra-Zeneca, Bayer Healthcare, Boehringer-Ingelheim, 
BMS/Pfizer, Novartis, Vifor 
Jeroen J. Bax:  Nothing to disclose 
Claudio Ceconi:  Nothing to disclose 
Martin R. Cowie:  Research grants from ResMed, Boston Scientific, and Bayer; personal fees 
from ResMed, Boston Scientific, Bayer, Servier, Novartis, St. Jude Medical, and Pfizer  
19 
 
Adam Crisp:  Employee of GlaxoSmithKline 
Fabienne Dominjon:  Employee of Servier 
Ian Ford:  Nothing to disclose 
Hossein-Ardeschir Ghofrani:  Personal fees (board membership, consultancy, paid lectures, or 
travel expenses) from Actelion, Bayer, GSK, Novartis, Pfizer, Bellerophon Therapeutics, United 
Therapeutics; research grants from Actelion, Bayer, Pfizer, Novartis. 
Savion Gropper:  Employee of Boehringer-Ingelheim GmBH & Co.KG 
Gerhard Hindricks:  Research grants from St. Jude Medical, Biotronik, Boston Scientific 
Mark A. Hlatky:  Nothing to disclose 
Richard Holcomb:  Nothing to disclose 
Narimon Honarpour:  Employee of Amgen 
J. Wouter Jukema:  Research grants from and CME speaker for meeting sponsored by Astellas, 
Astra Zeneca, Bayer, Biotronik, Boston Scientific, Daiichi Sankyo, Lilly, Genzyme, Medtronic, 
Merck Schering Plough, Pfizer, Orbus Neich, Novartis, Roche, Servier, Sanofi Aventis, The 
Netherlands Heart Foundation, Interuniversity Cardiology Institute of the Netherlands, European 
Community Framework KP7 Programme 
Albert M. Kim:  Employee of Pfizer 
Michael Kunz:  Employee of Bayer Healthcare 
Martin Lefkowitz:  Employee of Novartis Pharmaceuticals Company 
 Chantal Le Floch:  Employee of Servier 
Ulf Landmesser:  Research grants from Pfizer and Roche; honoraria (lecture and advisory) from 
Roche, MSD, Sanofi, and Amgen 
Theresa A. McDonagh:  Personal fees (honoraria) from Novartis, Vifor, ZS Pharma 
20 
 
John J. McMurray:  Nothing to disclose 
Bela Merkely:  Personal fees (lectures and advisory board membership) from Orion Pharma 
Milton Packer:  Nothing to disclose 
Krishna Prasad:  Nothing to disclose. 
James Revkin:  Nothing to disclose. 
Giuseppe Rosano:  Nothing to disclose 
Ransi Somaratne:  Employee and shareholder of Amgen, Inc. 
Wendy Gattis Stough:  Personal fees from European Society of Cardiology, Relypsa, Covis, 
Stealth Peptides 
Adriaan A. Voors:  Research grant from Novartis Pharmaceuticals, Singulex, Sphingotec, 
Trevena, and Vifor; personal fees from Novartis Pharmaceuticals, Servier, Bayer, Boehringer 
Ingelheim, Cardio3Biosciences, Celladon, GSK, Merck/MSD, Singulex, Trevena, and Vifor; 
non-financial support from Alere and Merck/MSD  
Frank Ruschitzka:  Nothing to disclose 
 
 
21 
 
 
 
References 
 
 1.   Zannad F, Garcia AA, Anker SD, Armstrong PW, Calvo G, Cleland JG, Cohn JN, 
Dickstein K, Domanski MJ, Ekman I, Filippatos GS, Gheorghiade M, Hernandez AF, 
Jaarsma T, Koglin J, Konstam M, Kupfer S, Maggioni AP, Mebazaa A, Metra M, 
Nowack C, Pieske B, Pina IL, Pocock SJ, Ponikowski P, Rosano G, Ruilope LM, 
Ruschitzka F, Severin T, Solomon S, Stein K, Stockbridge NL, Stough WG, Swedberg K, 
Tavazzi L, Voors AA, Wasserman SM, Woehrle H, Zalewski A, McMurray JJ. Clinical 
outcome endpoints in heart failure trials: a European Society of Cardiology Heart Failure 
Association consensus document. Eur J Heart Fail 2013;15:1082-1094. 
 2.   Cordoba G, Schwartz L, Woloshin S, Bae H, Gotzsche PC. Definition, reporting, and 
interpretation of composite outcomes in clinical trials: systematic review. BMJ 
2010;341:c3920. 
 3.   Freemantle N, Calvert M, Wood J, Eastaugh J, Griffin C. Composite outcomes in 
randomized trials: greater precision but with greater uncertainty? JAMA 2003;289:2554-
2559. 
 4.   European Network for Health Technology Assessment.  Endpoints used for relative 
effectiveness assessment of pharmaceuticals:  Clinical Endpoints. 
https://eunethta.fedimbo.belgium.be/sites/5026.fedimbo.belgium.be/files/Clinical%20end
points.pdf Last updated:  2013; Accessed on:  2/15/15. 
 5.   Jackson N, Atar D, Borentain M, Breithardt G, van Eickels M, Endres M, Fraass U, 
Friede T, Hannachi H, Janmohamed S, Kreuzer J, Landray M, Lautsch D, Le Floch C, 
22 
 
Mol P, Naci H, Samani N, Svensson A, Thorstensen C, Tijssen J, Vandzhura V, Zalewski 
A, Kirchhof P. Improving clinical trials for cardiovascular diseases:  a position paper 
from the Cardiovascular Roundtable of the European Society of Cardiology. European 
Heart Journal 2015; DOI: http://dx.doi.org/10.1093/eurheartj/ehv213. 
 6.   Roe MT, Mahaffey KW, Ezekowitz JA, Alexander JH, Goodman SG, Hernandez A, 
Temple T, Berdan L, Califf RM, Harrington RA, Peterson ED, Armstrong PW. The 
future of cardiovascular clinical research in North America and beyond-addressing 
challenges and leveraging opportunities through unique academic and grassroots 
collaborations. Am Heart J 2015;169:743-750. 
 7.   Moses H, III, Matheson DH, Cairns-Smith S, George BP, Palisch C, Dorsey ER. The 
anatomy of medical research: US and international comparisons. JAMA 2015;313:174-
189. 
 8.   Gomez G, Gomez-Mateu M, Dafni U. Informed choice of composite end points in 
cardiovascular trials. Circ Cardiovasc Qual Outcomes 2014;7:170-178. 
 9.   Pogue J, Thabane L, Devereaux PJ, Yusuf S. Testing for heterogeneity among the 
components of a binary composite outcome in a clinical trial. BMC Med Res Methodol 
2010;10:49. 
 10.   Pogue J, Devereaux PJ, Thabane L, Yusuf S. Designing and analyzing clinical trials with 
composite outcomes: consideration of possible treatment differences between the 
individual outcomes. PLoS One 2012;7:e34785. 
 11.   Pfeffer MA, Swedberg K, Granger CB, Held P, McMurray JJ, Michelson EL, Olofsson 
B, Ostergren J, Yusuf S, Pocock S, CHARM Investigators and Committees. Effects of 
23 
 
candesartan on mortality and morbidity in patients with chronic heart failure: the 
CHARM-Overall programme. Lancet 2003;362:759-766. 
 12.   Wolbers M, Koller MT, Stel VS, Schaer B, Jager KJ, Leffondre K, Heinze G. Competing 
risks analyses: objectives and approaches. Eur Heart J 2014;35:2936-2941. 
 13.   Ferreira-Gonzalez I, Busse JW, Heels-Ansdell D, Montori VM, Akl EA, Bryant DM, 
onso-Coello P, Alonso J, Worster A, Upadhye S, Jaeschke R, Schunemann HJ, 
Permanyer-Miralda G, Pacheco-Huergo V, Domingo-Salvany A, Wu P, Mills EJ, Guyatt 
GH. Problems with use of composite end points in cardiovascular trials: systematic 
review of randomised controlled trials. BMJ 2007;334:786. 
 14.   Swedberg K, Komajda M, Bohm M, Borer JS, Ford I, Dubost-Brama A, Lerebours G, 
Tavazzi L. Ivabradine and outcomes in chronic heart failure (SHIFT): a randomised 
placebo-controlled study. Lancet 2010;376:875-885. 
 15.   Bohm M, Borer J, Ford I, Gonzalez-Juanatey JR, Komajda M, Lopez-Sendon J, Reil JC, 
Swedberg K, Tavazzi L. Heart rate at baseline influences the effect of ivabradine on 
cardiovascular outcomes in chronic heart failure: analysis from the SHIFT study. Clin 
Res Cardiol 2013;102:11-22. 
 16.   Cohn JN, Tognoni G, Valsartan Heart Failure Trial Investigators. A randomized trial of 
the angiotensin-receptor blocker valsartan in chronic heart failure. N Engl J Med 
2001;345:1667-1675. 
 17.   Armstrong PW, Westerhout CM, Van de Werf F, Califf RM, Welsh RC, Wilcox RG, 
Bakal JA. Refining clinical trial composite outcomes: an application to the Assessment of 
the Safety and Efficacy of a New Thrombolytic-3 (ASSENT-3) trial. Am Heart J 
2011;161:848-854. 
24 
 
 18.   Buyse M. Generalized pairwise comparisons of prioritized outcomes in the two-sample 
problem. Stat Med 2010;29:3245-3257. 
 19.   Pocock SJ, Ariti CA, Collier TJ, Wang D. The win ratio: a new approach to the analysis 
of composite endpoints in clinical trials based on clinical priorities. Eur Heart J 
2012;33:176-182. 
 20.   Rauch G, Jahn-Eimermacher A, Brannath W, Kieser M. Opportunities and challenges of 
combined effect measures based on prioritized outcomes. Stat Med 2014;33:1104-1120. 
 21.   Rauch G, Rauch B, Schuler S, Kieser M. Opportunities and challenges of clinical trials in 
cardiology using composite primary endpoints. World J Cardiol 2015;7:1-5. 
 22.   Subherwal S, Anstrom KJ, Jones WS, Felker MG, Misra S, Conte MS, Hiatt WR, Patel 
MR. Use of alternative methodologies for evaluation of composite end points in trials of 
therapies for critical limb ischemia. Am Heart J 2012;164:277-284. 
 23.   Cleland JG. How to assess new treatments for the management of heart failure: 
composite scoring systems to assess the patients' clinical journey. Eur J Heart Fail 
2002;4:243-247. 
 24.   Dev S, Clare RM, Felker GM, Fiuzat M, Warner SL, O'Connor CM. Link between 
decisions regarding resuscitation and preferences for quality over length of life with heart 
failure. Eur J Heart Fail 2012;14:45-53. 
 25.   Stevenson LW, Hellkamp AS, Leier CV, Sopko G, Koelling T, Warnica JW, Abraham 
WT, Kasper EK, Rogers JG, Califf RM, Schramm EE, O'Connor CM. Changing 
preferences for survival after hospitalization with advanced heart failure. J Am Coll 
Cardiol 2008;52:1702-1708. 
25 
 
 26.   Packer M. Proposal for a new clinical end point to evaluate the efficacy of drugs and 
devices in the treatment of chronic heart failure. J Card Fail 2001;7:176-182. 
 27.   Redfield MM, Chen HH, Borlaug BA, Semigran MJ, Lee KL, Lewis G, LeWinter MM, 
Rouleau JL, Bull DA, Mann DL, Deswal A, Stevenson LW, Givertz MM, Ofili EO, 
O'Connor CM, Felker GM, Goldsmith SR, Bart BA, McNulty SE, Ibarra JC, Lin G, Oh 
JK, Patel MR, Kim RJ, Tracy RP, Velazquez EJ, Anstrom KJ, Hernandez AF, Mascette 
AM, Braunwald E. Effect of Phosphodiesterase-5 Inhibition on Exercise Capacity and 
Clinical Status in Heart Failure With Preserved Ejection Fraction: A Randomized 
Clinical Trial. JAMA 2013;1-10. 
 28.   Abraham WT, Young JB, Leon AR, Adler S, Bank AJ, Hall SA, Lieberman R, Liem LB, 
O'Connell JB, Schroeder JS, Wheelan KR. Effects of cardiac resynchronization on 
disease progression in patients with left ventricular systolic dysfunction, an indication for 
an implantable cardioverter-defibrillator, and mildly symptomatic chronic heart failure. 
Circulation 2004;110:2864-2868. 
 29.   Packer M, Colucci W, Fisher L, Massie BM, Teerlink JR, Young J, Padley RJ, Thakkar 
R, Delgado-Herrera L, Salon J, Garratt C, Huang B, Sarapohja T. Effect of levosimendan 
on the short-term clinical course of patients with acutely decompensated heart failure. 
JACC Heart Fail 2013;1:103-111. 
 30.   Hindricks G, Taborsky M, Glikson M, Heinrich U, Schumacher B, Katz A, Brachmann J, 
Lewalter T, Goette A, Block M, Kautzner J, Sack S, Husser D, Piorkowski C, Sogaard P. 
Implant-based multiparameter telemonitoring of patients with heart failure (IN-TIME): a 
randomised controlled trial. Lancet 2014;384:583-590. 
26 
 
 31.   Mozaffarian D, Benjamin EJ, Go AS, Arnett DK, Blaha MJ, Cushman M, de FS, Despres 
J, Fullerton HJ, Howard VJ, Huffman MD, Judd SE, Kissela BM, Lackland DT, 
Lichtman JH, Lisabeth LD, Liu S, Mackey RH, Matchar DB, McGuire DK, Mohler ER, 
III, Moy CS, Muntner P, Mussolino ME, Nasir K, Neumar RW, Nichol G, Palaniappan L, 
Pandey DK, Reeves MJ, Rodriguez CJ, Sorlie PD, Stein J, Towfighi A, Turan TN, Virani 
SS, Willey JZ, Woo D, Yeh RW, Turner MB. Heart Disease and Stroke Statistics-2015 
Update: A Report From the American Heart Association. Circulation 2015;131:e29-
e322. 
 32.   Packer M, Narahara KA, Elkayam U, Sullivan JM, Pearle DL, Massie BM, Creager MA. 
Double-blind, placebo-controlled study of the efficacy of flosequinan in patients with 
chronic heart failure. Principal Investigators of the REFLECT Study. J Am Coll Cardiol 
1993;22:65-72. 
 33.   Galie N, Hoeper MM, Humbert M, Torbicki A, Vachiery JL, Barbera JA, Beghetti M, 
Corris P, Gaine S, Gibbs JS, Gomez-Sanchez MA, Jondeau G, Klepetko W, Opitz C, 
Peacock A, Rubin L, Zellweger M, Simonneau G. Guidelines for the diagnosis and 
treatment of pulmonary hypertension: the Task Force for the Diagnosis and Treatment of 
Pulmonary Hypertension of the European Society of Cardiology (ESC) and the European 
Respiratory Society (ERS), endorsed by the International Society of Heart and Lung 
Transplantation (ISHLT). Eur Heart J 2009;30:2493-2537. 
 34.   Taichman DB, Ornelas J, Chung L, Klinger JR, Lewis S, Mandel J, Palevsky HI, Rich S, 
Sood N, Rosenzweig EB, Trow TK, Yung R, Elliott CG, Badesch DB. Pharmacologic 
therapy for pulmonary arterial hypertension in adults: CHEST guideline and expert panel 
report. Chest 2014;146:449-475. 
27 
 
 35.   Anker SD, Agewall S, Borggrefe M, Calvert M, Jaime CJ, Cowie MR, Ford I, Paty JA, 
Riley JP, Swedberg K, Tavazzi L, Wiklund I, Kirchhof P. The importance of patient-
reported outcomes: a call for their comprehensive integration in cardiovascular clinical 
trials. Eur Heart J 2014;35:2001-2009. 
 36.   Food and Drug Administration. Patient-Reported Outcome Measures:  Use in Medical 
Product Development to Support Labeling Claims. Guidance for Industry 2009. 
 37.   European Medicines Agency.  Innovative drug development approaches:  final report 
from the EMEA/CHMP think-tank group on innovative drug development. 
http://www.ema.europa.eu/docs/en_GB/document_library/Other/2009/10/WC500004913.
pdf Last updated:  2007; Accessed on:  4/30/15. 
 38.   European Medicines Agency.  Pilot project on adaptive licensing. 
http://www.ema.europa.eu/docs/en_GB/document_library/Other/2014/03/WC500163409.
pdf Last updated:  3-19-2014; Accessed on:  6/26/14. 
 39.   Eichler HG, Oye K, Baird LG, Abadie E, Brown J, Drum CL, Ferguson J, Garner S, 
Honig P, Hukkelhoven M, Lim JC, Lim R, Lumpkin MM, Neil G, O'Rourke B, Pezalla 
E, Shoda D, Seyfert-Margolis V, Sigal EV, Sobotka J, Tan D, Unger TF, Hirsch G. 
Adaptive licensing: taking the next step in the evolution of drug approval. Clin 
Pharmacol Ther 2012;91:426-437. 
 40.   European Medicines Agency.  Guideline on good pharmacovigilance practices (GVP):  
Module VIII Post authorisation safety studies (Rev 1). 
http://www.ema.europa.eu/docs/en_GB/document_library/Scientific_guideline/2012/06/
WC500129137.pdf Last updated:  2013; Accessed on:  4/30/15. 
28 
 
 41.   Rosano GMC, Anker S, Marrocco W, Coats AJS. Adaptive licensing:  A way forward in 
the approval process of new therapeutic agents in Europe. Clinical Trials and Regulatory 
Science in Cardiology 2015;1:1-2. 
 42.   Anker SD, McMurray JJ. Time to move on from 'time-to-first': should all events be 
included in the analysis of clinical trials? Eur Heart J 2012;33:2764-2765. 
 43.   Dunlay SM, Shah ND, Shi Q, Morlan B, VanHouten H, Long KH, Roger VL. Lifetime 
costs of medical care after heart failure diagnosis. Circ Cardiovasc Qual Outcomes 
2011;4:68-75. 
 44.   Bradley EH, Curry LA, Krumholz HM. Strategies to reduce heart failure readmissions. 
JAMA 2014;311:1160. 
 45.   Joynt KE, Jha AK. A path forward on Medicare readmissions. N Engl J Med 
2013;368:1175-1177. 
 46.   Rogers JK, McMurray JJ, Pocock SJ, Zannad F, Krum H, van Veldhuisen DJ, Swedberg 
K, Shi H, Vincent J, Pitt B. Eplerenone in patients with systolic heart failure and mild 
symptoms: analysis of repeat hospitalizations. Circulation 2012;126:2317-2323. 
 47.   Borer JS, Bohm M, Ford I, Komajda M, Tavazzi L, Sendon JL, Alings M, Lopez-de-Sa 
E, Swedberg K. Effect of ivabradine on recurrent hospitalization for worsening heart 
failure in patients with chronic systolic heart failure: the SHIFT Study. Eur Heart J 
2012;33:2813-2820. 
 48.   Rogers JK, Pocock SJ, McMurray JJ, Granger CB, Michelson EL, Ostergren J, Pfeffer 
MA, Solomon SD, Swedberg K, Yusuf S. Analysing recurrent hospitalizations in heart 
failure: a review of statistical methodology, with application to CHARM-Preserved. Eur 
J Heart Fail 2014;16:33-40. 
29 
 
 49.   Rogers JK, Jhund PS, Perez AC, Bohm M, Cleland JG, Gullestad L, Kjekshus J, van 
Veldhuisen DJ, Wikstrand J, Wedel H, McMurray JJ, Pocock SJ. Effect of rosuvastatin 
on repeat heart failure hospitalizations: the CORONA Trial (Controlled Rosuvastatin 
Multinational Trial in Heart Failure). JACC Heart Fail 2014;2:289-297. 
 50.   Amorim LD, Cai J. Modelling recurrent events: a tutorial for analysis in epidemiology. 
Int J Epidemiol 2015;44:324-333. 
 51.   Abraham WT, Adamson PB, Bourge RC, Aaron MF, Costanzo MR, Stevenson LW, 
Strickland W, Neelagaru S, Raval N, Krueger S, Weiner S, Shavelle D, Jeffries B, Yadav 
JS. Wireless pulmonary artery haemodynamic monitoring in chronic heart failure: a 
randomised controlled trial. Lancet 2011;377:658-666. 
 52.   Rogers, J.  Recurrent events analysis, not so straightforward! 
http://www.statisticsviews.com/details/feature/5786631/Recurrent-events-analysis-not-
so-straightforward.html Last updated:  1-28-0014; Accessed on:  1/28/14. 
 53.   Novartis Pharmaceuticals.  Efficacy and safety of LCZ696 compared to valsartan on 
morbidity and mortality in heart failure patients with preserved ejection fraction 
(PARAGON-HF). https://clinicaltrials.gov/ct2/show/NCT01920711 Last updated:  2014; 
Accessed on:  5/30/15. 
 54.   Committee for Medicinal Products for Human Use (CHMP). Guideline on the choice of 
the non-inferiority margin. EMEA/CPMP/EWP/21 58/99 2005. 
 55.   European Medicines Agency Committee for Medicinal Products for Human Use 
(CHMP). Guideline on missing data in confirmatory clinical trials 
(EMA/CPMP/EWP/1776/99). http://www ema europa 
eu/docs/en_GB/document_library/Scientific_guideline/2010/09/WC500096793 pdf 2010. 
30 
 
 56.   Senn S. Disappointing dichotomies. Pharmaceut Statist 2003;2:239-240. 
 57.   Lewis JA. In defence of the dichotomy. Pharmaceut Statist 2004;3:77-79. 
 58.   Hawkins NM, Petrie MC, Burgess MI, McMurray JJ. Selecting patients for cardiac 
resynchronization therapy: the fallacy of echocardiographic dyssynchrony. J Am Coll 
Cardiol 2009;53:1944-1959. 
 59.   Snapinn SM, Jiang Q. Responder analyses and the assessment of a clinically relevant 
treatment effect. Trials 2007;8:31. 
 60.   Vaduganathan M, Greene SJ, Ambrosy AP, Gheorghiade M, Butler J. The disconnect 
between phase II and phase III trials of drugs for heart failure. Nat Rev Cardiol 
2013;10:85-97. 
 61.   Hayward RA, Kent DM, Vijan S, Hofer TP. Multivariable risk prediction can greatly 
enhance the statistical power of clinical trial subgroup analysis. BMC Med Res Methodol 
2006;6:18. 
 62.   Kent DM, Rothwell PM, Ioannidis JP, Altman DG, Hayward RA. Assessing and 
reporting heterogeneity in treatment effects in clinical trials: a proposal. Trials 
2010;11:85. 
 63.   The CONSENSUS Trial Study Group. Effects of enalapril on mortality in severe 
congestive heart failure. Results of the Cooperative North Scandinavian Enalapril 
Survival Study (CONSENSUS). N Engl J Med 1987;316:1429-1435. 
 64.   The SOLVD Investigators. Effect of enalapril on mortality and the development of heart 
failure in asymptomatic patients with reduced left ventricular ejection fractions. N Engl J 
Med 1992;327:685-691. 
31 
 
 65.   The SOLVD Investigators. Effect of enalapril on survival in patients with reduced left 
ventricular ejection fractions and congestive heart failure. N Engl J Med 1991;325:293-
302. 
 66.   Cohn JN, Johnson G, Ziesche S, Cobb F, Francis G, Tristani F, Smith R, Dunkman WB, 
Loeb H, Wong M, . A comparison of enalapril with hydralazine-isosorbide dinitrate in 
the treatment of chronic congestive heart failure. N Engl J Med 1991;325:303-310. 
 67.   Cohn JN, Tognoni G, Glazer RD, Spormann D, Hester A. Rationale and design of the 
Valsartan Heart Failure Trial: a large multinational trial to assess the effects of valsartan, 
an angiotensin-receptor blocker, on morbidity and mortality in chronic congestive heart 
failure. J Card Fail 1999;5:155-160. 
 68.   Pitt B, Poole-Wilson PA, Segal R, Martinez FA, Dickstein K, Camm AJ, Konstam MA, 
Riegger G, Klinger GH, Neaton J, Sharma D, Thiyagarajan B. Effect of losartan 
compared with captopril on mortality in patients with symptomatic heart failure: 
randomised trial--the Losartan Heart Failure Survival Study ELITE II. Lancet 
2000;355:1582-1587. 
 69.   MERIT-HF Investigators. Effect of metoprolol CR/XL in chronic heart failure: 
Metoprolol CR/XL Randomised Intervention Trial in Congestive Heart Failure (MERIT-
HF). Lancet 1999;353:2001-2007. 
 70.   Packer M, Coats AJ, Fowler MB, Katus HA, Krum H, Mohacsi P, Rouleau JL, Tendera 
M, Castaigne A, Roecker EB, Schultz MK, DeMets DL. Effect of carvedilol on survival 
in severe chronic heart failure. N Engl J Med 2001;344:1651-1658. 
 71.   CIBIS II Investigators. The Cardiac Insufficiency Bisoprolol Study II (CIBIS-II): a 
randomised trial. Lancet 1999;353:9-13. 
32 
 
 72.   The Beta Blocker Evaluation of Survival Trial Investigators. A trial of the beta-blocker 
bucindolol in patients with advanced chronic heart failure. N Engl J Med 2001;344:1659-
1667. 
 73.   Taylor AL, Ziesche S, Yancy C, Carson P, D'Agostino R, Jr., Ferdinand K, Taylor M, 
Adams K, Sabolinski M, Worcel M, Cohn JN. Combination of isosorbide dinitrate and 
hydralazine in blacks with heart failure. N Engl J Med 2004;351:2049-2057. 
 74.   Packer M, O'Connor CM, Ghali JK, Pressler ML, Carson PE, Belkin RN, Miller AB, 
Neuberg GW, Frid D, Wertheimer JH, Cropp AB, DeMets DL. Effect of amlodipine on 
morbidity and mortality in severe chronic heart failure. Prospective Randomized 
Amlodipine Survival Evaluation Study Group. N Engl J Med 1996;335:1107-1114. 
 75.   Packer M, Carson P, Elkayam U, Konstam MA, Moe G, O'Connor C, Rouleau JL, 
Schocken D, Anderson SA, DeMets DL. Effect of amlodipine on the survival of patients 
with severe chronic heart failure due to a nonischemic cardiomyopathy: results of the 
PRAISE-2 study (prospective randomized amlodipine survival evaluation 2). JACC 
Heart Fail 2013;1:308-314. 
 76.   Pitt B, Zannad F, Remme WJ, Cody R, Castaigne A, Perez A, Palensky J, Wittes J. The 
effect of spironolactone on morbidity and mortality in patients with severe heart failure. 
Randomized Aldactone Evaluation Study Investigators. N Engl J Med 1999;341:709-717. 
 77.   Zannad F, McMurray JJ, Drexler H, Krum H, van Veldhuisen DJ, Swedberg K, Shi H, 
Vincent J, Pitt B. Rationale and design of the Eplerenone in Mild Patients Hospitalization 
And SurvIval Study in Heart Failure (EMPHASIS-HF). Eur J Heart Fail 2010;12:617-
622. 
33 
 
 78.   Pitt B, Pfeffer MA, Assmann SF, Boineau R, Anand IS, Claggett B, Clausell N, Desai 
AS, Diaz R, Fleg JL, Gordeev I, Harty B, Heitner JF, Kenwood CT, Lewis EF, O'Meara 
E, Probstfield JL, Shaburishvili T, Shah SJ, Solomon SD, Sweitzer NK, Yang S, 
McKinlay SM. Spironolactone for heart failure with preserved ejection fraction. N Engl J 
Med 2014;370:1383-1392. 
 79.   McMurray JJ, Packer M, Desai AS, Gong J, Lefkowitz MP, Rizkala AR, Rouleau JL, Shi 
VC, Solomon SD, Swedberg K, Zile MR. Angiotensin-neprilysin inhibition versus 
enalapril in heart failure. N Engl J Med 2014;371:993-1004. 
 80.   Moss AJ, Hall WJ, Cannom DS, Klein H, Brown MW, Daubert JP, Estes NA, III, Foster 
E, Greenberg H, Higgins SL, Pfeffer MA, Solomon SD, Wilber D, Zareba W. Cardiac-
resynchronization therapy for the prevention of heart-failure events. N Engl J Med 
2009;361:1329-1338. 
 81.   Tang AS, Wells GA, Talajic M, Arnold MO, Sheldon R, Connolly S, Hohnloser SH, 
Nichol G, Birnie DH, Sapp JL, Yee R, Healey JS, Rouleau JL. Cardiac-resynchronization 
therapy for mild-to-moderate heart failure. N Engl J Med 2010;363:2385-2395. 
 82.   Bardy GH, Lee KL, Mark DB, Poole JE, Packer DL, Boineau R, Domanski M, Troutman 
C, Anderson J, Johnson G, McNulty SE, Clapp-Channing N, vidson-Ray LD, Fraulo ES, 
Fishbein DP, Luceri RM, Ip JH. Amiodarone or an implantable cardioverter-defibrillator 
for congestive heart failure. N Engl J Med 2005;352:225-237. 
 83.   Cuffe MS, Califf RM, Adams KF, Jr., Benza R, Bourge R, Colucci WS, Massie BM, 
O'Connor CM, Pina I, Quigg R, Silver MA, Gheorghiade M. Short-term intravenous 
milrinone for acute exacerbation of chronic heart failure: a randomized controlled trial. 
JAMA 2002;287:1541-1547. 
34 
 
 84.   Konstam MA, Gheorghiade M, Burnett JC, Jr., Grinfeld L, Maggioni AP, Swedberg K, 
Udelson JE, Zannad F, Cook T, Ouyang J, Zimmer C, Orlandi C. Effects of oral 
tolvaptan in patients hospitalized for worsening heart failure: the EVEREST Outcome 
Trial. JAMA 2007;297:1319-1331. 
 85.   O'Connor CM, Starling RC, Hernandez AF, Armstrong PW, Dickstein K, Hasselblad V, 
Heizer GM, Komajda M, Massie BM, McMurray JJ, Nieminen MS, Reist CJ, Rouleau 
JL, Swedberg K, Adams KF, Jr., Anker SD, Atar D, Battler A, Botero R, Bohidar NR, 
Butler J, Clausell N, Corbalan R, Costanzo MR, Dahlstrom U, Deckelbaum LI, Diaz R, 
Dunlap ME, Ezekowitz JA, Feldman D, Felker GM, Fonarow GC, Gennevois D, Gottlieb 
SS, Hill JA, Hollander JE, Howlett JG, Hudson MP, Kociol RD, Krum H, Laucevicius A, 
Levy WC, Mendez GF, Metra M, Mittal S, Oh BH, Pereira NL, Ponikowski P, Tang WH, 
Tanomsup S, Teerlink JR, Triposkiadis F, Troughton RW, Voors AA, Whellan DJ, 
Zannad F, Califf RM. Effect of nesiritide in patients with acute decompensated heart 
failure. N Engl J Med 2011;365:32-43. 
 86.   McMurray JJ, Teerlink JR, Cotter G, Bourge RC, Cleland JG, Jondeau G, Krum H, Metra 
M, O'Connor CM, Parker JD, Torre-Amione G, van Veldhuisen DJ, Lewsey J, Frey A, 
Rainisio M, Kobrin I. Effects of tezosentan on symptoms and clinical outcomes in 
patients with acute heart failure: the VERITAS randomized controlled trials. JAMA 
2007;298:2009-2019. 
 87.   Mebazaa A, Nieminen MS, Packer M, Cohen-Solal A, Kleber FX, Pocock SJ, Thakkar R, 
Padley RJ, Poder P, Kivikko M. Levosimendan vs dobutamine for patients with acute 
decompensated heart failure: the SURVIVE Randomized Trial. JAMA 2007;297:1883-
1891. 
35 
 
 88.   Teerlink JR, Cotter G, Davison BA, Felker GM, Filippatos G, Greenberg BH, 
Ponikowski P, Unemori E, Voors AA, Adams KF, Jr., Dorobantu MI, Grinfeld LR, 
Jondeau G, Marmor A, Masip J, Pang PS, Werdan K, Teichman SL, Trapani A, Bush 
CA, Saini R, Schumacher C, Severin TM, Metra M. Serelaxin, recombinant human 
relaxin-2, for treatment of acute heart failure (RELAX-AHF): a randomised, placebo-
controlled trial. Lancet 2013;381:29-39. 
 89.   Efficacy, Safety, and Tolerability of Serelaxin When Added to Standard Therapy in AHF. 
http://www.clinicaltrials.gov/ct2/show/NCT01870778 Last updated:  11-13-2013; 
Accessed on:  1/17/14. 
 90.   Efficacy and Safety of Ularitide for the Treatment of Acute Decompensated Heart Failure 
(TRUE-AHF). http://www.clinicaltrials.gov/ct2/show/NCT01661634 Last updated:  10-1-
2014; Accessed on:  11/19/14. 
 
 
 Table 1.  Advantages and Disadvantages of Composite Endpoints 
Advantages Disadvantages 
Reduces sample size and improves trial 
efficiency if each component is 
modifiable by treatment  
 Power depends on number of 
events not number of patients 
May reduce power if some components of the 
composite are unaffected by treatment 
 
May allow adequate accrual of events 
over shorter follow-up 
Length of follow-up may be inadequate to characterize 
safety profile of a therapy intended for chronic use 
Captures multiple aspects of treatment 
effect (not limited to survival) 
Overall treatment effect may be driven by components 
of lesser importance (i.e. the least serious events 
usually occur with the greatest frequency); 
Treatment effects on different components may be 
directionally different.   
Avoids competing risk In time-to-first event analyses, the first event may not 
be the most serious  
Reduces need for multiple comparisons 
and allocation of type 1 error across 
different endpoint 
Individual components still need to be reported 
separately (usually as secondary endpoints);  
Insufficient power to draw conclusions about 
treatment effects for all components of composite; 
Uncertainty regarding worrisome trends in 
components of the composite. 
HF = heart failure; MI = myocardial infarction 
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Table 2.  Characteristics of Robust Composite Endpoints 
A Composite Endpoint should: 
1. Provide reliable and precise estimates of efficacy and safety 
2. Be clinically meaningful or relevant to physicians, patients, and care providers in terms of 
characterising disease progression, stabilization, or reversal 
3. Meaningfully characterise the burden of disease for patients 
4. Yield information that could be used in conjunction with other data to determine societal 
valuation of new therapies or interventions 
5. Improve the efficiency of clinical trials while maintaining high validity and quality 
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Table 3.  Areas of Uncertainty, and Priorities for Future Research 
Topic Description 
Component 
Selection 
1.  Involve regulators early in discussion of which components will be included in a composite endpoint; may differ 
between acute and chronic heart failure trials 
2.  Explicitly state the rationale for using a composite in the study protocol 
Clinical status 
composite endpoints 
1.  Which variables accurately reflect an unbiased assessment of a patient’s clinical status and burden of disease? 
2.  How can clinical composite endpoints be translated clinically (in terms of magnitude of effect and clinical relevance)? 
3.  How can quality of extended life be assessed? 
4.  Propose a quantitative assessment of the concordance of components of composite endpoints 
Recurrent event 
analysis 
1.  Methodology needs to be further studied and refined (e.g., how to deal with event clustering, ensure analysis is not 
driven by small proportion of patients). 
2.  How to confirm accuracy of assumptions and simulations used in modeling? 
3.  Involve regulators in planning modeling techniques for recurrent event analyses 
4.  Perform sensitivity analyses using standard time-to-event analysis 
5.  How to interpret results if recurrent event analysis results differ substantially in magnitude or direction from time-to-
first event analysis. 
 Supplemental Appendix Table 1.  Composite Endpoints in Heart Failure Clinical Trials 
Trial Primary Endpoint 
CONSENSUS63 All-cause mortality 
SOLVD-P64 All-cause mortality 
SOLVD-T65 All-cause mortality 
V-HeFT II66 All-cause mortality 
Val-HeFT16;67 Co-primary endpoints 
All-cause mortality 
Mortality and morbidity (cardiac arrest with resuscitation, 
hospitalization for heart failure, administration of IV inotropic 
or vasodilator drugs for ≥4 hours without hospitalization) 
CHARM11 Overall program:  All-cause mortality 
Individual trials:  Cardiovascular death or heart failure 
hospitalization 
ELITE II68 All-cause mortality 
MERIT-HF69 All-cause mortality 
COPERNICUS70 All-cause mortality 
CIBIS-II71 All-cause mortality 
BEST72 All-cause mortality 
A-HeFT73 Composite score made up of weighted values for death from 
any cause, a first hospitalization for heart failure during the 18-
month follow-up period, and change in the quality of life at 6 
months. 
Supplemental Appendix Table 1.  Composite Endpoints in Heart Failure Clinical Trials 
(continued) 
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Trial Primary Endpoint 
PRAISE74 All-cause mortality or cardiovascular morbidity (defined as 
hospitalization for at least 24 hours for acute pulmonary 
edema, severe hypoperfusion, acute myocardial infarction, or 
sustained or hemodynamically destabilizing ventricular 
tachycardia or fibrillation) 
PRAISE II75 All-cause mortality 
RALES76 All-cause mortality 
SHIFT14 Cardiovascular death or HF hospitalization 
EMPHASIS-HF77 Cardiovascular death or HF hospitalization 
TOPCAT78 Composite of death from CV causes, aborted cardiac arrest, or 
hospitalization for the management of heart failure 
PARADIGM-HF79 Cardiovascular death or HF hospitalization 
MADIT-CRT80 All-cause mortality or non-fatal HF events (signs/symptoms 
consistent with HF that was responsive to IV decongestive 
therapy on an outpatient basis or an augmented decongestive 
regimen with oral or parenteral medications during an in-
hospital stay) 
RAFT81 All-cause mortality or HF leading to hospitalization 
SCD-HeFT82 All-cause mortality 
OPTIME83 Cumulative days of hospitalization for cardiovascular causes 
EVEREST Outcome84 Dual primary endpoints of all-cause mortality and 
Supplemental Appendix Table 1.  Composite Endpoints in Heart Failure Clinical Trials 
(continued) 
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Trial Primary Endpoint 
cardiovascular death or hospitalization for heart failure 
ASCEND85 Two co-primary endpoints:  change in self-reported dyspnea at 
6 and 24 hours after study-drug initiation and the composite 
endpoint of rehospitalization for HF and death from any cause 
VERITAS86 Change from baseline in dyspnea over first 24 hours of 
treatment (individual studies) 
Incidence of death or worsening HF at 7 days (combined 
studies) 
REVIVE29 Composite clinical score:  Improved (patients considered 
themselves moderately or markedly improved at all pre-
specified time points and showed no evidence of clinical 
deterioration); Unchanged (not improved or worse); Worse 
(died within 5 days, persistent or unresponsive HF symptoms 
after first 24 hrs of randomized therapy or worsening HF 
anytime within 5 days that required a rescue intervention 
specifically to relieve the symptoms, or patients considered 
themselves to have moderately or markedly worsened on 
global assessment at any of the follow-up time points). 
SURVIVE87 All-cause mortality at 180 days 
RELAX-AHF88 Two primary efficacy endpoints:  change in patient-reported 
dyspnea by AUC of the VAS scores from baseline to day 5; 
Supplemental Appendix Table 1.  Composite Endpoints in Heart Failure Clinical Trials 
(continued) 
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Trial Primary Endpoint 
moderately or markedly improved patient reported dyspnea 
relative to the start of study drug assessed by 7-level Likert 
scale at 6, 12, and 24 hours 
RELAX-AHF-289 Time to confirmed cardiovascular death through 180 days and 
time to worsening heart failure through 5 days (also 
considering death), with all-cause mortality through 180 days 
pre-specified as a safety endpoint. 
TRUE-HF90 Two primary efficacy endpoints:  1) improvement in a 
hierarchical clinical composite endpoint (assessed at 6, 24, and 
48 hours after start of study drug) including patient global 
assessment of symptomatic improvement, lack of 
improvement, or worsening; persistent or worsening heart 
failure requiring pre-specified mechanical or pharmacologic 
interventions, and all-cause death; 2) freedom from 
cardiovascular death throughout the duration of the trial. 
AUC = area under the curve; CV = cardiovascular; HF = heart failure; VAS = visual analog scale 
 
